文献速递腹部技术与安全US

超声引导衰减参数:用于预测超重/肥胖患者代谢功能障碍相关脂肪性肝病进展的肝脏脂肪定量技术

Ultrasound-guided attenuation parameter: a liver fat quantification technique for forecasting the progression of metabolic dysfunction-associated steatotic liver disease in overweight/obese patients.
PubMed 文献 · Clin Radiol · 2025-02-14

研究纳入328例超重/肥胖患者(MASLD组225例、单纯超重/肥胖组103例)及236例年龄性别匹配健康对照,比较超声引导衰减参数成像的衰减系数差异。MASLD组、超重/肥胖组、对照组AC分别为0.73±0.08、0.57±0.04、0.54±0.07 dB-1·cm-1·MHz-1,组间差异有统计学意义(P<0.05)。AC、BMI、内脏脂肪为超重/肥胖患者MASLD的危险因素,AC联合BMI及内脏脂肪的预测模型AUC为0.997,诊断敏感度96.4%、特异度98.1%。

要点

  • MASLD组AC为0.73±0.08 dB-1·cm-1·MHz-1,高于单纯超重/肥胖组0.57±0.04及对照组0.54±0.07(P<0.05)。
  • 超重/肥胖患者MASLD预测AC最佳截断值为≥0.635 dB-1·cm-1·MHz-1,AUC为0.993。
  • AC联合BMI及内脏脂肪的预测模型AUC为0.997,诊断敏感度96.4%、特异度98.1%。

核心结论

  • UGAP可用于超重/肥胖患者MASLD的临床筛查并动态追踪疾病进展。
  • AC联合BMI及内脏脂肪预测模型可提高UGAP评估超重/肥胖患者MASLD的准确性。

研究设计与样本

  • 研究纳入328例超重/肥胖患者,其中MASLD组225例、单纯超重/肥胖组103例,另选同期年龄性别匹配的健康对照236例。
  • 采用独立样本T检验和多元logistic回归分析筛选超重/肥胖患者MASLD的危险因素,并建立预测模型评估诊断效能。
  • 采用Pearson相关分析探讨AC与临床指标的关系。

关键影像表现/征象

  • MASLD组AC为0.73±0.08 dB-1·cm-1·MHz-1,单纯超重/肥胖组为0.57±0.04 dB-1·cm-1·MHz-1,正常对照组为0.54±0.07 dB-1·cm-1·MHz-1,组间差异有统计学意义(P<0.05)。

诊断标准与关键数值

  • 超重/肥胖患者预测MASLD的AC最佳截断值为≥0.635 dB-1·cm-1·MHz-1,AUC为0.993。
  • BMI最佳截断值为≥27.58 kg/m2,AUC为0.792。
  • 内脏脂肪厚度最佳截断值为≥66.115 mm,AUC为0.708。
  • AC联合BMI及内脏脂肪的预测模型AUC为0.997,诊断敏感度96.4%、特异度98.1%,预测效能大于单一AC指标及AC+BMI双变量预测模型。

临床应用与阅片要点

  • 在超重/肥胖患者中,AC、BMI及内脏脂肪为预测MASLD的危险因素。
  • UGAP可用于超重/肥胖患者MASLD的临床筛查及动态追踪疾病进展。
  • 将AC与BMI及内脏脂肪预测模型联合可提高UGAP评估超重/肥胖患者MASLD的准确性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To investigate the application value of ultrasonic attenuation parameter imaging (UGAP) in the assessment of metabolic dysfunction-associated steatotic liver disease (MASLD) in overweight and obese patients.

MATERIAL AND METHODS: A total of 328 overweight/obese patients-225 in the MASLD group and 103 in the simple overweight/obese group-were chosen from XX between August 2023 and August 2024. As the typical control group, 236 healthy individuals who were matched for age and gender were chosen during the same period. The attenuation coefficient (AC) differences between the groups were compared, and Pearson correlation analysis was used to look into the relationship between AC and clinical indicators. A prediction model was created, the diagnostic efficacy was examined, and MASLD risk factors in overweight and obese patients were screened using the independent sample T-test and multiple logistic regression analysis.

RESULTS: AC of the MASLD group, overweight and obese group, and normal control group were (0.73 ± 0.08), (0.57 ± 0.04), and (0.54 ± 0.07) dB-1·cm-1·MHz-1. There was a statistically significant difference between the groups (P<0.05). In patients who were overweight or obese, AC, BMI, and visceral fat were the risk factors for predicting MASLD. The optimal cut-off values were AC ≥0.635dB-1·cm-1·MHz-1, BMI ≥27.58kg/m2, and visceral fat thickness (VFT) ≥66.115 mm. The areas under the receiver operating characteristic (ROC) curve were 0.993, 0.792, and 0.708. The area under ROC curve of AC combined with BMI and visceral fat was 0.997, and the prediction efficiency was greater than that of the single AC index and that of the AC + BMI bivariate prediction model. The diagnostic sensitivity and specificity were 96.4% and 98.1%.

CONCLUSION: UGAP can be utilised for clinical screening to assess the prevalence of MASLD in patients who are overweight or obese and to dynamically track the progression of the disease. In patients who are overweight or obese, the accuracy of the UGAP assessment of MASLD can be increased by combining AC with BMI and a visceral fat prediction model.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Meng F, Pian L, Wang Q, et al. Ultrasound-guided attenuation parameter: a liver fat quantification technique for forecasting the progression of metabolic dysfunction-associated steatotic liver disease in overweight/obese patients. Clin Radiol. 2025. PMID: 40199113. doi:10.1016/j.crad.2025.106854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。